Wont the news announced today about amprenavir's possible penetration of the blood- brain barrier make it more appealing to doctors? If the efficacy in other aspects is similar, wont this put Amprenavir one step ahead of the competition? Just thinking alot, feel free to disagree.
You must have good connection with Bear Sterns, I just received their Highlight today, my broker never call or inform me any information. I am in big lost just this stock so far. Please keep us inform in this board, thanks.
Can you summarize what the report stated about VRTX? We all know about the protease inhibitor, which will enter a crowded market. It seems that their inhibitor may not be able to distinguish itself from the others currently available, ie, modest market penetration. They have some interesting developing programs, esp. HepC. But we know nothing about that since their release of the structures of protease and helicase. Also, this is a competitive landscape: all major pharma companies and numerous biotech companies have similar programs.